Evidence map›Paper›PMID 39499900›Full record

ArticleJCI insight2024

All-in-one AAV-mediated Nrl gene inactivation rescues retinal degeneration in Pde6a mice.

Zhiquan Liu, Siyu Chen, Chien-Hui Lo, Qing Wang, Yang Sun

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. DownregulatingInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. International journal of biological sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhiquan LiuDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, California, USA.
Siyu ChenDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, California, USA.
Chien-Hui LoDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, California, USA.
Qing WangDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, California, USA.
Yang SunDepartment of Ophthalmology, Stanford University School of Medicine, Palo Alto, California, USA.

Funding

The role of primary cilia in glaucoma pathogenesisR01EY025295 · NEI · STANFORD UNIVERSITY · PI Yang Sun · 2016 to 2026
$3.5M
Phosphoinositide signaling in glaucoma: rescue strategies for Lowe syndromeR01EY032159 · NEI · STANFORD UNIVERSITY · PI SUN, YANG · 2021 to 2024
$1.6M
Shedding light on glaucoma: optogenetics regulation of ciliary phosphoinositidesI01CX001481 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI SUN, YANG · 2017 to 2025
–
CSRD VA I01 CX001481NEI NIH HHS R01 EY025295NEI NIH HHS R01 EY032159
6 · The paper itself

Abstract

Retinitis pigmentosa (RP) is a complex group of inherited retinal diseases characterized by progressive death of photoreceptor cells and eventual blindness. Pde6a, which encodes a cGMP-specific phosphodiesterase, is a crucial pathogenic gene for autosomal recessive RP (RP43); there is no effective therapy for this form of RP. The compact CRISPR/Staphylococcus aureus Cas9 (CRISPR/SaCas9) system, which can be packaged into a single adeno-associated virus (AAV), holds promise for simplifying effective gene therapy. Here, we demonstrated that all-in-one AAV-SaCas9-mediated Nrl gene inactivation can efficiently prevent retinal degeneration in a RP mouse model with Pde6anmf363/nmf363 mutation. We screened single-guide RNAs capable of efficiently editing the mouse Nrl gene in N2a cells and then achieved effective gene editing by using a single AAV to codeliver SaCas9 and an optimal Nrl-sg2 into the mouse retina. Excitingly, in vivo inactivation of Nrl improved photoreceptor cell survival and rescued retinal function in treated Pde6a-deficient mice. Thus, we showed that a practical, gene-independent method, AAV-SaCas9-mediated Nrl inactivation, holds promise for future therapeutic applications in patients with RP.

Indexed as

Cyclic Nucleotide Phosphodiesterases, Type 6DependovirusDisease Models, AnimalEye ProteinsGene EditingGenetic TherapyRetinal DegenerationAnimalsBasic-Leucine Zipper Transcription FactorsCRISPR-Cas SystemsHumansMiceMutationRetinaRetinitis PigmentosaBasic-Leucine Zipper Transcription FactorsCyclic Nucleotide Phosphodiesterases, Type 6Eye ProteinsNrl protein, mousePde6a protein, mouseGene therapyGenetic diseasesOphthalmologyTherapeutics

Identifiers

PMID39499900
PMCPMC11665581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.